司库奇尤单抗治疗活动性狼疮肾炎的III期SELUNE研究及开放标签扩展研究结果
SELUNE核心研究为III期随机、安慰剂对照、双盲研究,评估司库奇尤单抗300 mg联合标准治疗用于活动性狼疮肾炎成人患者。因预设无效性分析显示司库奇尤单抗较安慰剂无临床获益,两项研究均提前终止;第52周完全肾脏缓解率司库奇尤单抗组24.2%低于安慰剂组36.3%,安全性相当。
要点
- 第52周完全肾脏缓解率司库奇尤单抗组24.2% vs 安慰剂组36.3%。
- 核心研究所有次要终点在两组间均无差异。
- 治疗中出现的不良事件发生率两组相当,未发现新的安全性信号。
核心结论
- 司库奇尤单抗在活动性狼疮肾炎患者中未显示出优于安慰剂的疗效,且耐受性良好,未检测到新的或非预期安全性信号。
研究设计与样本
- 核心研究为III期随机、安慰剂对照、双盲研究,计划 duration 104周,患者随机接受司库奇尤单抗300 mg或安慰剂(前4周给药,随后每月维持剂量),所有患者均接受标准治疗背景方案。
- 完成核心研究104周治疗的患者可进入开放标签扩展研究(计划 duration 至多260周),接受司库奇尤单抗300 mg每4周一次。
- 核心研究主要终点为第52周达到完全肾脏缓解(CRR)的患者比例。
主要发现
- 核心研究第52周达到CRR的患者比例司库奇尤单抗组为24.2%,安慰剂组为36.3%,司库奇尤单抗组低于安慰剂组。
- 核心研究所有次要终点在司库奇尤单抗组与安慰剂组之间均无差异。
- 治疗中出现的不良事件发生率在司库奇尤单抗组与安慰剂组之间相当。
- 扩展研究因纳入数据分析的患者数少(n=31),结果不可解释。
关键数值与推荐
- 核心研究主要终点第52周CRR:司库奇尤单抗组24.2% vs 安慰剂组36.3%。
- 扩展研究数据分析纳入患者数n=31,结果不可解释。
临床怎么用
- 核心研究预设无效性分析显示司库奇尤单抗较安慰剂无临床获益,两项研究均提前终止。
局限性
- 两项研究均在核心研究预设无效性分析显示司库奇尤单抗较安慰剂无临床获益后提前终止。
- 扩展研究因纳入数据分析的患者数少(n=31),结果不可解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of s.c. secukinumab 300 mg combined with standard of care (SoC) in adult patients with active LN. METHODS: The core study was a phase III randomized, placebo-controlled, double-blind study (planned duration: 104 weeks) of patients with active LN. Eligible patients were randomized to receive secukinumab 300 mg or placebo for the first 4 weeks, followed by a monthly maintenance dose, with all patients receiving a SoC background regimen. Patients completing the 104-week treatment of the core study were eligible for an open-label extension study (planned duration: up to 260 weeks) to receive secukinumab 300 mg every 4 weeks. The primary end point of the core study was the proportion of patients achieving complete renal response (CRR) at week 52. RESULTS: Both studies were terminated early, following a planned futility analysis in the core study that showed no clinically meaningful benefit of secukinumab over placebo. In the core study, the proportion of patients achieving CRR at week 52 was lower after receiving secukinumab (24.2%) than after receiving the placebo (36.3%). No differences were observed between the secukinumab and placebo groups in any of the secondary end points of the core study. The incidence of treatment-emergent adverse events was comparable between the secukinumab and placebo groups. In the extension study, the results were not interpretable, owing to the low patient number included in the data analysis (n = 31). CONCLUSION: Secukinumab did not demonstrate superior efficacy over placebo in patients with active LN. Secukinumab was well-tolerated with no new or unexpected safety signals detected. TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT04181762, NCT04181762 (Novartis study code: CAIN457Q12301). https://www.clinicaltrials.gov/study/NCT05232864, NCT05232864 (Novartis study code: CAIN457Q12301E1).
引用
- Zhao MH, Cons Molina F, Aroca G, et al. Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study. Rheumatology (Oxford). 2026. PMID: 41092316. doi:10.1093/rheumatology/keaf536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。